Sun Pharmaceutical Earnings Summary — Q4 FY2026

• Revenue grew 12.8% year-on-year to ₹14,612 Cr, demonstrating sustained demand for specialty and chronic portfolios.
• Operating Profit Margin (OPM) contracted to 27% from 32% in the previous quarter, driven by higher operating expenses which reached ₹10,658 Cr.
• Net Profit surged 25.8% annually to ₹2,710 Cr compared to Mar 2025, though it fell significantly from the Dec 2025 record of ₹3,381 Cr.
• Borrowings increased to ₹4,627 Cr by March 2026, nearly doubling from ₹2,362 Cr recorded in March 2025.
• The tax rate remained stable at 23% compared to the prior-year quarter, though profitability was aided by a spike in Other Income to ₹458 Cr.
• Sun Pharma maintains its status as India's largest domestic pharmaceutical player with an 8%+ market share.
• Specialty product contribution continues to stabilize overall margins compared to the volatile US generic commoditization cycle.

Management remains focused on the specialty pivot across dermatology and ophthalmology, aiming to offset US generic pricing pressures through high-margin complex molecules.

Deteriorating

While year-on-year growth remains strong, the sequential decline in revenue and the sharp 500 basis point drop in OPM since last quarter indicate near-term cost pressures.

The outlook remains positive for long-term compounding as the specialty portfolio matures, though regulatory scrutiny of manufacturing facilities and R&D gestation periods present ongoing risks.